ACN Newswire
HONG KONG, Sep 1, 2025 – (ACN Newswire) – On August 29, Everest Medicines (1952.HK) announced its interim results for the six months ended June 30, 2025. The Company’s total revenue for the first half of 2025 reached RMB 446 million, representing 48% year-over-year growth, while operating expenses as a percentage of revenue decreased by 40.1 percentage points…
Read More
Everest Medicines Announces 2025 Interim Results: ‘Dual-Engine’ Strategy Driving Strong Synergies Between Commercialization and R&D
Margherita Guillemette
20:19
HONG KONG, Sep 1, 2025 – (ACN Newswire) – On August 29, Everest Medicines (1952.HK) announced its interim results for the six months ended June 30, 2025. The Company’s total revenue for the first half of 2025 reached RMB 446 million, representing 48% year-over-year growth, while operating expenses as a percentage of revenue decreased by
